GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2021

H D

HOUSE BILL 93

Committee Substitute Favorable 3/10/21 PROPOSED COMMITTEE SUBSTITUTE H93-PCS30336-BC-6

Short Tit	le: R	Req. Opioid Antagonist Ed. w/Opioid Scripts.	(Public)
Sponsors	s:		
Referred	to:		
		February 17, 2021	
		A BILL TO BE ENTITLED	
AN ACT REQUIRING EACH HEALTH CARE PRACTITIONER WHO PRESCRIBES AN			
OPIOID MEDICATION TO A PATIENT TO PROVIDE EDUCATION ON AND OFFER			
A PR	RESCR	IPTION FOR AN OPIOID ANTAGONIST FOR THAT PATIEN	T UNDER
CER'	TAIN (CIRCUMSTANCES AND FOR CERTAIN PURPOSES.	
The Gene	eral Ass	sembly of North Carolina enacts:	
	SEC	TION 1. Article 1 of Chapter 90 of the General Statutes is amended	by adding
a new sec			
"§ 90-12.8. Requirement to provide opioid antagonist education.			
<u>(a)</u>		practitioner, as defined in G.S. 90-87(22), except, for purposes of this	
-		l not include (i) a veterinarian, (ii) an animal hospital, (iii) a veterina	
	_	are provider, or (v) a palliative care provider, writes a prescription for	
		controlled substance described in G.S. 90-90(1), and any of the following in the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and any of the following substance described in G.S. 90-90(1), and g.S. 90-90(1)	
	<u>practītī</u>	oner shall provide the education as described in subsections (b) and	(c) of this
section:	(1)		'11'
	<u>(1)</u>	The prescription dosage for the patient is 50 or more morphine	milligram
	(2)	equivalents of an opioid medication per day. The School of the American and associated in C. S. 00,00(1) in	له و ما اسم و مسم
	<u>(2)</u>	The Schedule II controlled substance described in G.S. 90-90(1) is	prescribed
	(2)	concurrently with a prescription for benzodiazepine.	and by but
	<u>(3)</u>	The patient presents with an increased risk for overdose, as eviden not limited to, (i) a patient with a history of overdose, (ii) a patient	•
		history of substance use disorder, or (iii) a patient at risk for ret	
		high dosage of a Schedule II controlled substance described in G.	
		to which the patient is no longer tolerant.	<u>3. 70 70(1)</u>
<u>(b)</u>	Cons	sistent with the existing standard of care, the practitioner shall prov	ide to each
		g a prescription pursuant to subsection (a) of this section education of	
-	-	the use of a drug approved by the federal Food and Drug Administr	
		st for the complete or partial reversal of opioid-induced respiratory de	
(c)		sistent with the existing standard of care, the practitioner shall provide	
more per	sons de	esignated by the patient receiving a prescription pursuant to subsection	(a) of this
section or, for a patient who is a minor, to the minor's parent, guardian, or person standing in loco			
parentis, education on overdose prevention and the use of a drug approved by the federal Food			
and Drug Administration as an opioid antagonist for the complete or partial reversal of			



opioid-induced respiratory depression.

2223

After providing the education required by subsection (b) or (c) of this section, the 1 (d) 2 practitioner shall offer a prescription for a drug approved by the federal Food and Drug 3 Administration as an opioid antagonist for the complete or partial reversal of opioid-induced 4 respiratory depression. 5 When dispensing a Schedule II controlled substance described in G.S. 90-90(1), and any of the criteria in subdivisions (1) through (3) of subsection (a) of this section apply, a 6 7 pharmacist shall do all of the following: 8 Ask the individual receiving the prescription if that individual has a (1) 9 prescription for an opioid antagonist and offer to fill the prescription if the 10 individual has one. 11 Advise the individual receiving the prescription that the State Health Director **(2)** has issued a statewide standing order allowing the pharmacist to dispense an 12 opioid antagonist without a specific prescription from the individual's 13 14 prescriber. The pharmacist shall also offer to dispense an opioid antagonist in 15 accordance with the statewide standing order. Communicate the details of the interaction back to the prescriber within 72 16 (3) 17 hours of dispensing the Schedule II controlled substance. Nothing in this section shall be construed to do either of the following: 18 <u>(f)</u> 19 Create a private right of action against a practitioner who fails to follow the (1) 20 requirements of this section. Limit a practitioner's liability for negligent diagnosis or treatment of a patient, 21 (2)

SECTION 2. This act becomes effective October 1, 2021.

as allowed under applicable State or federal law."

Page 2 House Bill 93 H93-PCS30336-BC-6